Intravesical chemotherapy given immediately after surgery for nonmuscle-invasive bladder cancer (NMIBC) is associated with a decrease in 30-day complication rates, according to study results presented at the Society of Urologic Oncology 2020 virtual annual meeting.
Using the American College of Surgeons’ National Surgical Quality Improvement Program database, Pratik Kanabur, MD, and Guilhereme Godoy, MD, of the Baylor College of Medicine in Houston, Texas, studied 52,407 patients who underwent transurethral resection of bladder tumor (TURBT) from 2005 to 2018. Of these, 2557 (4.9%) received postoperative intravesical chemotherapy (POIC).
Patients receiving POIC had a significantly lower 30-day complication rate than those who did not (4.5% vs 7.5%). Common complications included sepsis, bleeding, and venous thromboembolic events. On multivariable analysis, POIC was significantly associated with an approximately 19% lower risk of postoperative complications. POIC was not associated with a higher 30-day mortality rate. Older age, longer operative time, resection of a large tumor, and ASA Class higher than 3 were significantly associated with an increased risk of postoperative complications.
Patients who received POIC were younger and more likely to be White and have a higher body mass index compared with those who did not receive POIC.
Kanabur P, Godoy G. Immediate postoperative intravesical instillation of chemotherapy after transurethral resection of bladder tumor: Findings from the National Surgical Quality Improvement Program database. Presented at the Society of Urologic Oncology 2020 virtual annual meeting, December 3-5. Poster 40.
This article originally appeared on Renal and Urology News